Cat. No.: DAB-0011847
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly129 of human Bif-1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SH3GLB1 |
| UniProt No. | Q9Y371 |
| Gene ID | 51100 |
| Gene Description | Bif-1/SH3GLB1/Endophilin-B1 is a member of the endophilin B family that was originally identified as a Bax binding protein through yeast two-hybrid screening. Bif-1 does not have significant homology to other Bcl-2 family members, but rather contains an N-terminal Bin-Amphiphysin-Rvs domain, typically involved in membrane dynamics, and a C-terminal SH3 domain. Overexpression of Bif-1 promotes Bax conformational change and apoptosis. Likewise, loss of Bif-1 inhibits Bax and Bak activation, cytochrome c release, and caspase activation. Bif-1 is localized to membranes of intracellular organelles and has been suggested to play a role in membrane dynamics, including that during autophagy. Bif-1 directly binds to UVRAG, forming a complex with Beclin-1, resulting in increased PI3-kinase class III/Vps34 activity required for autophagosome maturation. Inhibition of GSK-3β, as seen during nutrient deprivation, results in increased expression of Bif-1, and can contribute to autophagic cell death. Research studies have shown that loss of Bif-1 promotes tumorigenesis, and decreased expression of Bif-1 has been noted in several cancer types. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
